// App-Quantinova.ai

4078 : Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study.

Researchers

Presenter

  • Bruno Sangro

Principal Investigators

  • Ignacio Melero

  • Thomas Cheung Yau

  • Chiun Hsu

  • Masatoshi Kudo

  • Todd S. Crocenzi

  • Tae-You Kim

  • Su Pin Choo

  • Jorg Trojan

  • Tim Meyer

  • Yoon-Koo Kang

  • Jeffrey Anderson

  • Christine Marie Dela Cruz

  • Lixin Lang

  • Jaclyn Neely

  • Anthony B. El-Khoueiry

Medical Centers

  • Clinica Universidad de Navarra, Pamplona, Spain

  • University of Hong Kong, Hong Kong, China

  • National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan

  • Kinki University Faculty of Medicine, Osaka, Japan

  • Providence Cancer Center, Portland, OR

  • National Cancer Centre Singapore, Singapore, Singapore

  • Goethe University, Frankfurt, Germany

  • The Royal Marsden Hospital, London, United Kingdom

  • Bristol-Myers Sqiubb, Princeton, NJ

  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

Locations

  • China

  • Japan

  • Taiwan

  • Singapore

  • Spain

  • Germany

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

  • Sorafenib

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT01658878

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved